Plain-English translation of NCT07657494 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This research study is testing whether two special types of imaging scans — called FAPI PET/CT and Grazytracer PET/CT — can help doctors predict how well your lymphoma will respond to treatment and what your long-term outlook might be. These scans look at specific things happening around your cancer cells that may give clues about whether your cancer will respond well to therapy. By studying these imaging patterns in nearly 100 patients, researchers hope to develop better tools to personalize your treatment plan.
Doctors currently struggle to predict early on whether a person's aggressive lymphoma will respond well to standard treatments or if it will come back. This imaging could help identify which patients need different treatment approaches sooner, potentially improving outcomes and avoiding unnecessary treatments that won't help.
You likely qualify if…
You likely don't qualify if…
You will come to the hospital or imaging center to have special PET/CT scans done. These scans use harmless tracers (dyes) injected into your bloodstream to show how your immune system and cancer cells are interacting. Some participants may have one type of scan, while others being considered for immunotherapy may have an additional scan. Your imaging results will be analyzed along with your medical records and how you respond to your cancer treatment over time.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China